Oncogenic magnesium transporter 1 upregulates programmed death-1-ligand 1 expression and contributes to growth and radioresistance of glioma cells through the ERK/MAPK signaling pathway

References

• Osswald M, Jung E, Sahm F, et al. Brain tumour cells interconnect to a functional and resistant network. Nature. 2015;528(7580):93–98.
   PubMed Web of Science ®Google Scholar
• Phillips RE, Soshnev AA, Allis CD. Epigenomic reprogramming as a driver of malignant glioma. Cancer Cell. 2020;38(5):647–660.
   PubMed Web of Science ®Google Scholar
• Huo T, Yang Y, Qian M, et al. Versatile hollow COF nanospheres via manipulating transferrin Corona for precise glioma-targeted drug delivery. Biomaterials. 2020;260:120305.
   PubMed Web of Science ®Google Scholar
• Mannino M, Chalmers AJ. Radioresistance of glioma stem cells: intrinsic characteristic or property of the ‘microenvironment-stem cell unit’? Mol Oncol. 2011;5(4):374–386.
   PubMed Web of Science ®Google Scholar
• Wu N, Veillette A. Immunology: magnesium in a signalling role. Nature. 2011;475(7357):462–463.
   PubMed Web of Science ®Google Scholar
• Wang G, Li Y, Li J, et al. microRNA-199a-5p suppresses glioma progression by inhibiting MAGT1. J Cell Biochem. 2019;120(9):15248–15254.
   PubMed Web of Science ®Google Scholar
• Zheng JM, Kong YY, Li YY, et al. MagT1 regulated the odontogenic differentiation of BMMSCs induced byTGC-CM via ERK signaling pathway. Stem Cell Res Ther. 2019;10(1):48.
   PubMedGoogle Scholar
• Yang LK, Zhu J, Chen YH, et al. Knockdown of angiopoietin-like protein 2 Inhibits proliferation and invasion in glioma cells via suppressing the erk/mapk signaling pathway. Oncol Res. 2017;25(8):1349–1355.
   PubMed Web of Science ®Google Scholar
• Wang P, Wang Z, Yan Y, et al. Psychological stress Up-Regulates CD147 expression through Beta-Arrestin1/ERK to promote proliferation and invasiveness of glioma cells. Front Oncol. 2020;10:571181.
   PubMed Web of Science ®Google Scholar
• Huang L, Li B, Tang S, et al. Mitochondrial KATP channels control glioma radioresistance by regulating ROS-Induced ERK activation. Mol Neurobiol. 2015;52(1):626–637.
   PubMed Web of Science ®Google Scholar
• Kang X, Li P, Zhang C, et al. The TLR4/ERK/PDL1 axis may contribute to NSCLC initiation. Int J Oncol. 2020;57(2):456–465.
   PubMed Web of Science ®Google Scholar
• Ma G, Liang Y, Chen Y, et al. Glutamine Deprivation Induces PD-L1 Expression via Activation of EGFR/ERK/c-Jun signaling in renal cancer. Mol Cancer Res. 2020;18(2):324–339.
   PubMed Web of Science ®Google Scholar
• Qiu XY, Hu DX, Chen WQ, et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochim Biophys Acta Mol Basis Dis. 2018;1864(5 Pt A):1754–1769.
   PubMed Web of Science ®Google Scholar
• Kohnke T, Krupka C, Tischer J, et al. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8:111.
   PubMed Web of Science ®Google Scholar
• Chen RQ, Liu F, Qiu XY, et al. The Prognostic and Therapeutic Value of PD-L1 in Glioma. Front Pharmacol. 2019;9:1503.
   PubMed Web of Science ®Google Scholar
• Vimalathas G, Kristensen BW. Expression, prognostic significance and therapeutic implications of PD-L1 in gliomas. Neuropathol Appl Neurobiol. 2022;48(1):e12767.
   PubMed Web of Science ®Google Scholar
• Litak J, Mazurek M, Grochowski C, et al. PD-L1/PD-1 axis in glioblastoma multiforme. Int J Mol Sci. 2019;20(21). DOI:10.3390/ijms20215347
   PubMed Web of Science ®Google Scholar
• Puigdelloses M, Garcia-Moure M, Labiano S, et al. CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models. J Immunother Cancer. 2021;9(7). DOI:10.1136/jitc-2021-002644
   PubMed Web of Science ®Google Scholar
• Wei J, Wang F, Kong LY, et al. miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Res. 2013;73(13):3913–3926.
   PubMed Web of Science ®Google Scholar
• Giles AJ, Hutchinson MND, Sonnemann HM, et al. Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6(1):51.
   PubMedGoogle Scholar
• Varghese F, Bukhari AB, Malhotra R, et al. IHC Profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PloS one. 2014;9(5):e96801.
   PubMed Web of Science ®Google Scholar
• Li H, Xia T, Guan Y, et al. Sevoflurane regulates glioma progression by Circ_0002755/miR-628-5p/MAGT1 axis. Cancer Manag Res. 2020;12:5085–5098.
   PubMed Web of Science ®Google Scholar
• Deason-Towne F, Perraud AL, Schmitz C. The Mg2+ transporter MagT1 partially rescues cell growth and Mg2+ uptake in cells lacking the channel-kinase TRPM7. FEBS Lett. 2011;585(14):2275–2278.
   PubMed Web of Science ®Google Scholar
• Cazzaniga A, Moscheni C, Trapani V, et al. The different expression of TRPM7 and MagT1 impacts on the proliferation of colon carcinoma cells sensitive or resistant to doxorubicin. Sci Rep. 2017;7:40538.
   PubMed Web of Science ®Google Scholar
• Cherepanova NA, Gilmore R. Mammalian cells lacking either the cotranslational or posttranslocational oligosaccharyltransferase complex display substrate-dependent defects in asparagine linked glycosylation. Sci Rep. 2016;6:20946.
   PubMed Web of Science ®Google Scholar
• Zheng K, Yang Q, Xie L, et al. Overexpression of MAGT1 is associated with aggressiveness and poor prognosis of colorectal cancer. Oncol Lett. 2019;18(4):3857–3862.
   PubMed Web of Science ®Google Scholar
• Li B, Liu YH, Sun AG, et al. MiR-130b functions as a tumor promoter in glioma via regulation of ERK/MAPK pathway. Eur Rev Med Pharmacol Sci. 2017;21(12):2840–2846.
   PubMed Web of Science ®Google Scholar
• Cao Y, Zhang L, Wang Y. Antitumor activity of Cedrelone in temozolomide-resistant human glioma cells is accompanied by mitochondrial mediated apoptosis, inhibition of angiogenesis, cell cycle disruption and modulation of ERK/MAPK signalling pathway. J BUON. 2019;24(3):1204–1209.
   PubMed Web of Science ®Google Scholar
• Jiang W, Jin G, Cai F, et al. Extracellular signal-regulated kinase 5 increases radioresistance of lung cancer cells by enhancing the DNA damage response. Exp Mol Med. 2019;51(2):1–20.
   Web of Science ®Google Scholar
• Affolter A, Fruth K, Brochhausen C, et al. Activation of mitogen-activated protein kinase extracellular signal-related kinase in head and neck squamous cell carcinomas after irradiation as part of a rescue mechanism. Head Neck. 2011;33(10):1448–1457.
   PubMed Web of Science ®Google Scholar
• Cho H, Matsumoto S, Fujita Y, et al. Trametinib plus 4-Methylumbelliferone exhibits antitumor effects by ERK Blockade and CD44 downregulation and affects PD-1 and PD-L1 in malignant pleural mesothelioma. J Thorac Oncol. 2017;12(3):477–490.
   PubMed Web of Science ®Google Scholar
• Xue S, Hu M, Iyer V, et al. Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. J Hematol Oncol. 2017;10(1):81.
   PubMedGoogle Scholar
• Ene CI, Kreuser SA, Jung M, et al. Anti-PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. Neuro Oncol. 2020;22(5):639–651.
   PubMed Web of Science ®Google Scholar
• D’Arrigo P, Digregorio M, Romano S, et al. The splicing FK506-binding protein-51 isoform plays a role in glioblastoma resistance through programmed cell death ligand-1 expression regulation. Cell Death Discov. 2019;5:137.
   PubMed Web of Science ®Google Scholar